Beclometasone/formoterol

Beclometasone/formoterol, sold under the brand name Fostair, is an inhalable fixed-dose combination drug for the treatment of asthma and chronic obstructive pulmonary disease (COPD).[1] It contains beclometasone dipropionate and formoterol fumarate dihydrate. It is inhaled.[1]

Beclometasone/formoterol
Combination of
Beclometasone dipropionateGlucocorticoid
Formoterol fumarateLong-acting β2 agonist
Clinical data
Trade namesFostair
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Inhalation
ATC code
Legal status
Legal status

It was approved for medical use in the United Kingdom in 2007,[1] and in Australia in February 2020.[4][5]

References
  1. "Fostair 100/6 micrograms per actuation pressurised inhalation solution - Summary of Product Characteristics (SmPC)". (emc). 3 March 2020. Retrieved 18 July 2020.
  2. "Fostair 200/6 micrograms per actuation pressurised inhalation solution - Summary of Product Characteristics (SmPC)". (emc). 13 February 2019. Retrieved 18 July 2020.
  3. "Fostair NEXThaler 200 micrograms/6 micrograms per actuation inhalation powder - Summary of Product Characteristics (SmPC)". (emc). 16 April 2019. Retrieved 18 July 2020.
  4. "Australian Product Information - Fostair 100/6 (Beclometasone dipropionate and formoterol (eformoterol) fumarate dihydrate) pressurised inhalation solution". Therapeutic Goods Administration (TGA). April 2020. Retrieved 22 September 2020.
  5. "AusPAR: Beclometasone dipropionate/formoterol (eformoterol) fumarate dihydrate". Therapeutic Goods Administration (TGA). 3 August 2020. Retrieved 22 September 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.